Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment;Interruptions du traitement antirétroviral chez 30 patients infectés par le VIH en succès virologique

Presse Medicale

Volumn 34, Issue 10 SUPPL., 2005, Pages

  Pavie, Juliette ^a   Porcher, Raphaël ^a   Fournier, Sandra ^a   Furco, André ^a   Tournoux, Caroline ^a   Palmer, Pierre ^a   Rabian, Claire ^a   Molina, Jean Michel ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIPODYSTROPHY; LIVER TOXICITY; LYMPHOCYTE COUNT; MALE; NEUROPATHY; RASH; RISK ASSESSMENT; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 20844441904     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Palella FJ jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
2. García F, Plana M, Vidal C, Cruceta A, O'Brien WA, Pantaleo G et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999; 13: F79-F86.
3. Martinez E, Mocroft A, García-Viejo M, Perez-Cuevas JB, Blanco JL, Mallolas J et al. A prospective cohort study on the risk for lipodystrophy in HIV-1 infected patients treated with protease inhibitor-containing regimens. Lancet 2001; 357: 592-8.
4. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
5. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-86.
6. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
7. Fagard C, Oxenius A, Gunthard H, Garcia F, Le Braz M, Mestre G et al. A prospective trial of structured treatment interruption in human immunodeficiency virus infection. Arch Intern Med 2003; 163: 1220.
8. Ananworanich J, Phanuphak N, Nuesch R, Apateerapong W, Rojnuckarin P, Ubolyam S et al. Reccuring thrombocytopenia associated with structured treatment interruption in patients with human immunodeficiency virus infection. Clin Infect Dis 2003; 37: 723-5.
9. Ananworanich J, Nuesch R, Le Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17: F33-F37.
10. Cardiello P, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005; 40: 594-600.
11. Schweighardt B, Ortiz G M, Grant R M, Wellons M, Miralles GD, Kostrikis LG et al. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS 2002; 16: 2342-4.
12. Martinez-Picado J, Morales-Lopetegi K, Wrin T, Prado JG, Frost SD, Petropoulos CJ et al. Selection of drug resistant HIV-1 mutants in response to repeated structured treatmen interruption. AIDS 2002; 16: 895-9.
13. Dybul M, Niels-Kraske E, Daucher M, Hertogs K, Hallahan CW, Csako G et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiecy virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 2003; 188: 388-96.
14. Daniel N, Schneider V, Pialoux G, Krivine A, Grabar S, Nguyen TH et al. Emergence of HIV-1 mutated strains after interruption of highly active antiretroviral therapy in chronically infected patients. AIDS 2003; 17: 2126-9.
15. Tarwater MT, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly antiretroviral therapy. Clin Infect Dis 2003; 37: 1541-8.
16. Giuntini R, Martinelli C, Ambu S, Bartolozzi D, Farese A, Boddi V et al. Prolonged interruption in chronic HIV infection: a new strategy? AIDS 2005; 19: 209-15.
17. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 2004; 18: 439-46.
18. Tebas P, Henry K, Mondy K, Deeks S, Valdez H, Cohen C et al. Effect of prolonged discontinuation antiretroviral therapy on CD4 T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. J Infect Dis 2002; 186: 851-4.